References
- Velenik V, Oblak I, Anderluh F. Quality of life in patients after combined modality treatment of rectal cancer: report of a prospective phase II study. Radiol Oncol 2008: 42: 207-14.
- Nordlinger B., Sorbye H., B. Glimelius, Poston G.J. Peri-operative FOLFOX4 chemoterapy and surgery for resectable liver metastases from colorectal cancer. Lancet 2008; 371: 963-5.
- Malafosse R, Penna C, Cunha AS, Nordlinger B. Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol 2001; 12: 887-94.
- Folprecht G, Grothey A, Alberts S, Raab H-R, Köhne C-H. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16: 1311-9.
- van Cutsem E, Bodoky G, Roh JK, Folprecht G, Park YS, van Laethem JL, et al. ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC). [Abstract O-3001]. ECCO 14 Abstract Book. Eur J Cancer Suppl 2007; 5(Suppl 4): 235.
- Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, et al. The CRYSTAL study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mCRC receiving first-line treatment with cetuximab or cetuximab plus FOLFIRI. [Abstract O-031]. Ann Oncol 2008; 19(Suppl 6): vi17-8.
- Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, et al. Resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593-602.
- Folprecht G, Gruenberger T, Hartmann JT, Lordick F, Stoehlmacher J, Bechstein W, et al. Randomized multicenter study of cetuximab plus FOLFOX or cetuximab plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-Study). [Abstract 510PD]. ESMO 2008. Ann Oncol 2008; 19(8): viii168.
- Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
- Salzt LB, Clarke S, Rubio ED, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with Oxaliplatin based chemotherapy as first line treatment in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 6: 2013-9.
- Booth C. Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm. [Correspondence]. J Clin Oncol 2008; 26: 4693-4.
- Saltz LB, Ahmad SA, Vauthey JN. Colorectal cancer: management of advanced disease. In: Kelsen DP, Daly MJ, Keren SE, Levin B, Tepper JE, editors. Gastrointestinal oncology. Philadelphia: Lippincott William & Wilkins; 2002. p. 825-52.
- Meta-analysis group in cancer. The efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
- Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol 2004; 22: 229-37.
- Cunningham D, Pyrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, et al. Randomised trial of itinotecan plus supporative care versus supporative care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
- Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000; 343: 905-14.
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-7.
- de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorine and fluorouracil with and without oxaliplatin as firstline treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
- Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 crčme. Radiol Oncol 2008: 42: 215-24.
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-74.
- Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008; 26: 5335-43.
- De Cerqueira Mathias C, Perazzo F, Simon S, Fein L4, Hidalgo J5, Murad A, et al. Cetuximab plus irinotecan in heavily-pretreated patients with mCRC: preliminary data from the LABEL study. [Abstract P-0159]. Ann Oncol 2007; 18(Suppl 7): vii72.
- Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H-J, et al. Cetuximab for the treatment of colorectal cancer. (NCIC CTG CO.17). N Engl J Med 2007; 357: 2040-8.
- Sobrero A, Hochster H, Luppi G, Kroening H4, Mulkerin D5, Chan A, et al. Cetuximab plus irinotecan in patients with mCRC who have failed prior oxaliplatin-based therapy: the EPIC trial. [Abstract O-0030]. Ann Oncol 2007; 18(Suppl 7): Vii20.
- Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25(12): 1539-44.
- Saltz L. In reply. [Correspondence]. J Clin Oncol 2008; 26: 4694-5.
- Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-34.